Ahmann AJ, Capehorn M, Charpentier G et al (2018) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial
FDA reported that some compounded pharmacies used different salt forms of semaglutide, which are different from the active ingredient found in FDA approved semaglutide products
Asad Niazi, internal medicine physician and medical advisor at Shed
These results have generated considerable scientific interest, though retatrutide remains an experimental compound and is not yet approved for clinical use in the UK or elsewhere
Recent breakthrough findings A 2024 study is our primary insight into the effect of semaglutide on breastfeeding
In 2019 alone, obesity-related medical care costs in the United States were estimated at approximately $173 billion.(2) These widespread health and economic burdens highlight the urgent need for effective obesity management